InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Smith L. Mary, Directrice du Développement. Director active across 2 companies, notably SpringWorks Therapeutics, Inc.. Aggregated, 11 reports have been published. History available since 13 July 2021. The latest transaction was filed on 4 January 2024 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Smith L. Mary
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
21,156 shares0Common StockSEC:0001104659-24-002380:0
5,720 sharesCommon StockSEC:0001104659-23-078084:0
1,068 shares@ US$26.416.1% of flowCommon StockSEC:0001104659-23-002695:0
22,663 sharesCommon StockSEC:0001104659-23-002318:0
1,551 shares@ US$28.479.8% of flowCommon StockSEC:0001104659-22-081242:0
6,092 shares0Common StockSEC:0001104659-22-077448:0
1,181 shares@ US$56.0622.9% of flowCommon StockSEC:0001104659-22-004463:0
1,772 shares@ US$56.0634.3% of flowCommon StockSEC:0001104659-22-003144:0
22,205 sharesCommon StockSEC:0001104659-22-002747:0
10,000 shares@ US$2.307.7% of flowCommon StockSEC:0001104659-21-125932:0
10,000 shares@ US$2.307.6% of flowCommon StockSEC:0001104659-21-092123:0
11 of 11 declarations
About Smith L. Mary
Smith L. Mary is Directrice du Développement and Chief Development Officer at SpringWorks Therapeutics, Inc. The declarant has 11 filings in total, and across the 11 sampled filings the observed transactions are awards, with amounts of EUR 87,934.28571533972, EUR 58,606.31570531389, EUR 43,525.08225211719, EUR 26,806.02195152965, EUR 19,828.29996808982 and EUR 19,532.28960935923, covering the period from 2021-07-14 to 2024-01-08.
